A Study of RC48-ADC in Subjects With Advanced Breast Cancer
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection
in subjects with advanced breast cancer with HER2 positive or HER2 low expression